Thus, the ex vivo selection or enrichment of CXCR3+ CD8+ T cells appears as a promising strategy for optimizing the efficacy of therapeutic concepts, which are based on the adoptive transfer of tumor-targeting T cells in the clinical context of CRC [25]. The gene discussed is CD8A; the disease is colorectal carcinoma.